ClinicalTrials.gg
RecruitingNCT06515184Updated May 1, 2026

Coenzyme Q10 for Gulf War Illness: A Replication Study

A Phase 3 interventional study of PharmaNord Bio-Quinone Active CoQ10 Gold 100mg and PharmaNord Placebo in Gulf War Syndrome, Persian Gulf Syndrome and Mitochondrial Disorder, Respiratory Chain, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of California, San Diego · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in Persian Gulf Syndrome with a site in United States — 9 open to participants now, 9 under way, 1 of them phase 3. Persian Gulf Syndrome · United States.

Planned enrollment
4th of 31
192 · median 53
Started
2024
with 1 other
Phase 3
4 of 41
1 open now
Registered
38th of 41
by date
Lead sponsor
2 of 41
University of California, San Diego

Among the 41 studies in Persian Gulf Syndrome with a site in United States, this one is the 4th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 38th registered.

Persian Gulf Syndrome

41 studies on the registry are indexed under Persian Gulf Syndrome; 9 are open to participants now.

Browse Persian Gulf Syndrome studies →

Open to participants now

9 of the 41 studies in Persian Gulf Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Persian Gulf Syndrome studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Persian Gulf Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.

03

Conditions studied

  • Gulf War Syndrome
  • Persian Gulf Syndrome
  • Mitochondrial Disorder, Respiratory Chain
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets both CDC and Kansas deployment and symptom inclusion criteria.
  • Does not have a disqualifying condition.
  • Able to travel to a local Quest facility for study blood draws.
  • Adequate internet access to allow ZoomPro visit participation and remote survey completion.
  • Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).
  • Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.

Exclusion criteria

Exclusion Criteria:

  • Participating in another clinical trial.
  • Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.
  • On Coumadin/ warfarin.
  • Unable to participate for the required duration of the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Active comparator
    CoQ10 Arm 1

    PharmaNord Ubiquinone 100mg/1x day

    Drug: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

  • Active comparator
    CoQ10 Arm 2

    PharmaNord Ubiquinone 100mg/3x day

    Drug: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

  • Placebo comparator
    Placebo Arm

    Placebo (made by PharmaNord, matches active treatment)

    Drug: PharmaNord Placebo

Interventions

  • DrugPharmaNord Bio-Quinone Active CoQ10 Gold 100mg

    Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

  • DrugPharmaNord Placebo

    Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

  • DrugPharmaNord Bio-Quinone Active CoQ10 Gold 100mg

    Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

06

What researchers measure

Primary outcomes

  1. Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. on placebo.

    All outcomes are assessed as change from baseline.

    Time frame: 3.5 months

Secondary outcomes

  1. Percent improved on timed chair rises from Gulf War Illness Modified Lower Extremity Summary Performance Score.

    All outcomes are assessed as change from baseline.

    Time frame: 3.5 months

  2. Mean change in single-item General Self-Rated Health (GSRH).

    All outcomes are assessed as change from baseline. 5 point scale, higher is good.

    Time frame: 3.5 months

  3. Individual GWI Symptoms

    7 validated single-item symptom self-ratings: headache; energy; fatigue with exertion, muscle pain; irritability; impatience; trouble recalling words/names. Each benefited with coQ10, p\<0.05 (two-sided), in the prior coQ10 trial.

    Time frame: 3.5, 7 months

  4. Relation of change in time to do five chair rises to change in blood level of coenzyme Q10

    Benefit to timed chair rises will relate to blood coQ10 change. This outcome assesses the relation between change in time to complete five chair rises (in seconds) to change in blood level of CoQ10 (in ug/mL). The prediction of change in time to perform five chair rises by change in coQ10 blood level (regression with robust standard errors).

    Time frame: 3.5, 7 months

  5. Effect of CoQ10 in the majority male subset on symptoms.

    Change in symptoms on coQ10 versus placebo will be assessed in men (male subset of sample).

    Time frame: 3.5, 7 months

  6. Effect of CoQ10 in the majority male subset on timed chair rises.

    Change in timed chair rises on coQ10 versus placebo will be assessed in men (male subset of sample).

    Time frame: 3.5, 7 months

  7. Effect of CoQ10 in the majority male subset on GSRH.

    Change in GSRH on coQ10 versus placebo will be assessed in men (male subset of sample).

    Time frame: 3.5, 7 months

Other outcomes

  1. The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on symptoms.

    Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on symptoms.

    Time frame: 3.5, 7 months

  2. The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on timed chair rises.

    Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on timed chair rises.

    Time frame: 3.5, 7 months

  3. The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on GSRH.

    Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on GSRH.

    Time frame: 3.5, 7 months

  4. Duration Effect on symptoms. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on symptoms.

    Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months).

    Time frame: 7 months

  5. Duration Effect on timed chair rises. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on timed chair rises.

    Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months).

    Time frame: 7 months

  6. Duration Effect on GSRH. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on GSRH.

    Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months).

    Time frame: 7 months

  7. Blood Pressure

    Specifically, change in blood pressure on coq10 versus placebo will be assessed considering those with low blood pressure at baseline separately from those with borderline or high blood pressure at baseline.

    Time frame: 3.5, 7 months

  8. Mitochondrial Function from blood spot card. Maximal respiration will be assessed by the "adopted transfer" technique.

    Time frame: 3.5, 7 months

  9. Mitochondrial Function from blood spot card. Spare capacity will be assessed by the "adopted transfer" technique.

    Time frame: 3.5, 7 months

  10. Inflammation (hsCRP) will be assessed as change from baseline and compared on active treatment vs. placebo.

    Time frame: 3.5, 7 months

  11. Oxidative Stress

    Time frame: 3.5, 7 months

  12. Liver Function. Alanine aminotransferase and aspartate aminotransferase will be assessed as change from baseline and compared on active treatment vs. placebo.

    Time frame: 3.5, 7 months

  13. Dropouts for Cause. The investigator will report participants who drop out for a reason.

    For instance, participants who transition from coQ10 to placebo might drop because of lost of needed benefits of coQ10 -- because the participant felt worse. Alternatively, participants who transition from placebo run-in to coQ10 might drop out due to problems like activation insomnia on active treatment. The number of dropouts will be compared on active treatment vs placebo, and the causes of dropout will be compared also. (Participants who drop because their physicians ask them to do so for some unrelated reason, not because the patient has had a problem or perceive a problem, will count as dropouts, but not as dropouts for "cause" -- cause here refers to a symptom change and/or medical event.) In addition to overall assessment, assessment of dropouts for cause will be evaluated stratified by whether the participant is transitioning from coQ10.

    Time frame: 3.5, 7 months

  14. Relation of change in symptoms to change in blood level of coenzyme Q10

    This outcome assesses the relation between change in symptoms to change in blood level of CoQ10 (in ug/mL).

    Time frame: 3.5 +/- 0.5 months (priority), and ~7 months

  15. Relation of change in single-item General Self-Rated Health (GSRH) to change in blood level of coenzyme Q10

    This outcome assesses the relation between change in single-item General Self-Rated Health (GSRH) to change in blood level of CoQ10 (in ug/mL). The GSRH is a 5 point scale, higher is good.

    Time frame: 3.5, 7 months

  16. Subset effects in those citing prior coQ10 use, stratified by whether benefit had been perceived.

    Time frame: 3.5, 7 months

  17. Analysis stratified by presence of symptoms compatible with sleep apnea

    For inclusion in sleep apnea stratum during analysis, the following will be qualifying: Diagnosed sleep apnea, nocturia, awaking from sleep gasping or choking (or observed by others gasping or choking during sleep), daytime hypersomnolence, night sweats, or awaking with headache or anxiety. This is exploratory, but each outcome will be stratified by sleep apnea-compatible problems.

    Time frame: 3.5, 7 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jul 23, 2024
StartActual
Sep 13, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06515184
Collaborators
United States Department of Defense
Responsible party
Beatrice Golomb (Professor of Medicine, University of California, San Diego) — Principal investigator
First posted
Jul 23, 2024
Start date
Sep 13, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 1, 2026

Study contacts

Janis B Ritchie, BSN
Contact
jbritchie@ucsd.edu
858-558-4950
Beatrice A Golomb, MD, PhD
principal investigator · University of California, San Diego

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion